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STATE-OF-THE-ART PAPERS STATE-OF-THE-ART PAPERSObesity and Cardiovascular Diseases 1345
Carl J. Lavie, Paul A. McAuley, Timothy S. Church, Richard V. Milani, Steven N. Blair
This state-of-the-art paper reviews the epidemiology of obesity and its effect on
cardiovascular physiology. The impact of morbid obesity on prognosis and the obesity
paradox are discussed. Finally, the beneﬁts of weight loss and exercise training are presented.STATE-OF-THE-ART PAPERSIncomplete Stent Apposition 1355
Guilherme F. Attizzani, Davide Capodanno, Yohei Ohno, Corrado Tamburino
Incomplete stent opposition (ISA) is characterized by the lack of contact of at least 1 stent
strut with the vessel wall in a segment not overlying a side branch. In this paper, the authors
review the mechanism, pathophysiology, and clinical aspects of ISA. Finally, strategies to
reduce this phenomenon are also discussed.VIEWPOINT VIEWPOINTPolypills: Essential Medicines 1368
Mark D. Huffman, Salim Yusuf
The World Health Organization has developed a Model List of Essential Medicines to guide
countries in the creation of national formularies and policies for access, quality, and use of
essential medicines as part of achieving the right to health. Fixed-dose combination or
polypill therapy has been shown to improve adherence by 33%, as compared with usual care
in cardiovascular disease secondary prevention. A polypill was, however, not included in the
updated 18th Model List of Essential Medicines. The authors of this paper provide
arguments to support the inclusion of such a pill in the list.(continued on page A-22)
APRIL 15, 2014 (continued) A-22CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGYEverolimus Versus Bare-Metal Stents in Octogenarians 1371
Adam de Belder, Jose M. de la Torre Hernandez, Ramon Lopez-Palop, Peter O’Kane,
Felipe Hernandez Hernandez, Julian Strange, Federico Gimeno, James Cotton, Jose F. Diaz Fernandez,
Pilar Carrillo Saez, Martyn Thomas, Eduardo Pinar, Nick Curzen, Jose A. Baz, Nina Cooter,
Inigo Lozano, Nicola Skipper, Derek Robinson, David Hildick-Smith,
on behalf of the XIMA Investigators
The objective of this study was to determine whether drug-eluting stents (DES) were
superior to bare-metal stents (BMS) in octogenarian patients with angina. The primary
endpoint was 1-year composite of death, myocardial infarction (MI), cerebrovascular
accident, target vessel revascularization (TVR), or major hemorrhage. A total of 800 patients
were randomized to BMS or DES. There was no difference in the primary endpoint between
groups; however, MI (8.7% vs. 4.3%) and TVR (7.0% vs. 2.0%) occurred more often in the
BMS cohort. The authors conclude that BMS and DES offer good clinical outcome in this
age group. However, DES was associated with a lower incidence of MI and TVR without an
increased incidence of major hemorrhage.
Editorial Comment: Mikkel M. Schoos, George D. Dangas, p. 1376INTERVENTIONAL CARDIOLOGYDrug-Eluting Balloon Versus Everolimus-Eluting Stent for In-Stent Restenosis 1378
Fernando Alfonso, Maria Jose Pérez-Vizcayno, Alberto Cárdenas, Bruno García del Blanco,
Bernhard Seidelberger, Andrés Iñiguez, Manuel Gómez-Recio, Mónica Masotti, M. Teresa Velázquez,
Juan Sanchís, Arturo García-Touchard, Javier Zueco, Armando Bethencourt, Rafael Melgares,
Angel Cequier, Antonio Dominguez, Vicente Mainar, José R. López-Mínguez, José Moreu, Vicens Martí,
Raúl Moreno, Pilar Jiménez-Quevedo, Nieves Gonzalo, Cristina Fernández, Carlos Macaya,
for the RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology
of the Spanish Society of Cardiology
The RIBS-V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs.
Everolimus-eluting Stent) trial compared the efﬁcacy of drug-eluting balloons (DEB) versus
everolimus-eluting stents (EES) in patients with bare-metal stent (BMS) in-stent restenosis
(ISR). A total of 189 patients with BMS-ISR were included, and the primary angiographic
endpoint was minimal lumen diameter at 9-month follow-up. At late angiography (median
249 days), patients in the EES arm had a signiﬁcantly larger minimal lumen diameter (2.36
 0.6 mm vs. 2.01  0.6 mm) and a lower % diameter stenosis (13  17% vs. 25  20%).
However, the occurrence of the combined clinical outcome measure (cardiac death,
myocardial infarction, and target vessel revascularization) and the need for target vessel
revascularization were similar in the 2 groups. The study shows that in patients with BMS-
ISR, both DEB and EES provide excellent clinical results; however, EES provides superior
late angiographic ﬁndings.(continued on page A-23)
APRIL 15, 2014 (continued) A-23INTERVENTIONAL CARDIOLOGYBioimpedance Analysis and Contrast-Induced Nephropathy 1387
Mauro Maioli, Anna Toso, Mario Leoncini, Nicola Musilli, Francesco Bellandi, Mitchell H. Rosner,
Peter A. McCullough, Claudio Ronco
The objective of this study was to evaluate the relationship between pre-procedural ﬂuid
status assessed by bioimpedance vector analysis (BIVA) and development of contrast-induced
acute kidney injury (CI-AKI). A total of 900 consecutive patients undergoing angiography
had ﬂuid status evaluated by BIVA by measuring the resistance/height (R/H) ratio. Pre-
procedural R/H ratios were signiﬁcantly higher in CI-AKI than in non–CI-AKI patients
(395 71 Ohm/m vs. 352 58 Ohm/m for females; 303 59 Ohm/m vs. 279 45 Ohm/m
for males), indicating lower ﬂuid volume in these subjects. Lower ﬂuid status as determined
by BIVA before contrast medium administration is a signiﬁcant and independent predictor of
CI-AKI in stable CAD patients.HEART FAILURETrends in LVAD Use and Outcomes 1395
Prateeti Khazanie, Bradley G. Hammill, Chetan B. Patel, Zubin J. Eapen, Eric D. Peterson,
Joseph G. Rogers, Carmelo A. Milano, Lesley H. Curtis, Adrian F. Hernandez
Khazanie and colleagues examined trends in mortality, readmission, and costs among
Medicare beneﬁciaries receiving ventricular assist devices (VADs) and association between
hospital-level procedure volume and outcomes. Among the 2,507 patients who received a
VAD during the study period (2006 to 2011), in-hospital mortality declined from 30% to
10%, 1-year mortality declined from 42% to 26%, and all-cause readmission was frequent
(82% and 81%). Hospitals with low procedure volumes had a higher risk of in-hospital and
1-year mortality; however, procedure volume was not associated with risk of readmission.(continued on page A-25)
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Melanie D. Everitt, Lynn A. Sleeper, Minmin Lu, Charles E. Canter, Elfriede Pahl,
James D. Wilkinson, Linda J. Addonizio, Jeffrey A. Towbin, Joseph Rossano, Rakesh K. Singh,
Jacqueline Lamour, Steven A. Webber, Steven D. Colan, Renee Margossian, Paul F. Kantor,
John L. Jefferies, Steven E. Lipshultz, for the Pediatric Cardiomyopathy Registry Investigators
The authors attempted to determine the incidence of and predictors for recovery of normal
echocardiographic function among children with idiopathic dilated cardiomyopathy (DCM).
A total of 741 subjects who had both depressed left ventricular (LV) function and LV
dilation at diagnosis and had at least 1 follow-up echocardiogram 30 days to 2 years from the
initial echocardiogram were included. The study revealed that at 2 years, 22% had recovered
normal LV function and size, 51% had died or undergone heart transplant, and 27% had a
persistently abnormal echocardiogram. Younger age (hazard ratio: 0.9) and lower LV
end-diastolic dimension z-score (hazard ratio: 0.75) independently predicted normalization.
The study concludes that children with idiopathic DCM can recover normal LV size and
function, particularly those younger and with less LV dilation at diagnosis.
Editorial Comment: Alan B. Lewis, p. 1414HEART RHYTHM DISORDERSEndocardial Ablation for Epicardial VT Substrate 1416
Yuki Komatsu, Matthew Daly, Frédéric Sacher, Hubert Cochet, Arnaud Denis, Nicolas Derval,
Laurence Jesel, Stephan Zellerhoff, Han S. Lim, Amir Jadidi, Isabelle Nault, Ashok Shah,
Laurent Roten, Patrizio Pascale, Daniel Scherr, Valerie Aurillac-Lavignolle, Mélèze Hocini,
Michel Haïssaguerre, Pierre Jaïs
The authors evaluated the feasibility and safety of epicardial substrate elimination using
endocardial radiofrequency (RF) delivery in patients with scar-related ventricular tachycardia
(VT). A total of 46 patients, 18 with ischemic cardiomyopathy, 13 with nonischemic dilated
cardiomyopathy, and 15 with arrhythmogenic right ventricular cardiomyopathy, received
endocardial ablation targeting local abnormal ventricular activities (LAVA) in the
endocardium (Endo-LAVA) and epicardium (Epi-LAVA), followed by epicardial ablation if
needed. Endocardial RF was associated with Epi-LAVA elimination at the facing site in
28% of applications, and complete or incomplete elimination was achieved in 61% of patients
overall. The authors concluded that elimination of Epi-LAVA using endocardial RF delivery
is feasible and may be used ﬁrst to reduce risk of epicardial ablation.
Editorial Comment: David J. Wilber, p. 1427(continued on page A-26)
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Peter Weeke, Jonathan D. Mosley, David Hanna, Jessica T. Delaney, Christian Shaffer,
Quinn S. Wells, Sara Van Driest, Jason H. Karnes, Christie Ingram, Yan Guo, Yu Shyr,
Kris Norris, Prince J. Kannankeril, Andrea H. Ramirez, Joshua D. Smith, Elaine R. Mardis,
Deborah Nickerson, Alfred L. George, Jr, Dan M. Roden
This study evaluated the contribution of rare genetic variants to the underlying genetic
framework predisposing to drug-induced long QT syndrome (diLQTS). Whole rare variant
analyses were performed on 65 diLQTS cases and 148 drug-exposed control patients.
Analysis revealed that rare variants in 7 genes were enriched in the diLQTS cases compared
with drug-exposed control patients. Further study, however, revealed that only 2 genes,
KCNE1 and ACN9, were consistently associated with diLQTS. Using next-generation
sequencing, rare variants in KCNE1 and ACN9 have been identiﬁed as associated with
diLQTS.
Editorial Comment: Lia Crotti, Peter J. Schwartz, p. 1438BIOMARKERShs-cTnT Assay Upper Reference Limits 1441
M. Odette Gore, Stephen L. Seliger, Christopher R. deFilippi, Vijay Nambi, Robert H. Christenson,
Ibrahim A. Hashim, Ron C. Hoogeveen, Colby R. Ayers, Wensheng Sun, Darren K. McGuire,
Christie M. Ballantyne, James A. de Lemos
Using data from the DHS (Dallas Heart Study), the ARIC (Atherosclerosis Risk in
Community) study, and the CHS (Cardiovascular Health Study), the investigators attempted
to determine the 99th percentile upper reference limit for high-sensitivity cardiac troponin T
assay (hs-cTnT). Individuals with recent hospitalization, overt cardiovascular disease, and
kidney disease (subcohort 1) and, additionally, subclinical structural heart disease (subcohort
2), were excluded. The 99th percentile values for hs-cTnT in the DHS, ARIC, and CHS
studies were 18, 22, and 36 ng/l, respectively (subcohort 2). Approximately 10% of men ages
65 to 74 years without cardiovascular disease had cTnT values above the threshold. This
study reveals that using a uniform 14 ng/l cutoff for the hs-cTnT assay may lead to
overdiagnosis of myocardial infarction in men and in the elderly.
Editorial Comment: Christopher M. Kramer, p. 1449
